Associations - CDKN2A deletion

CDKN2A deletion CDKN2A deletion	B Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia	CDKN2A deletion CDKN2A deletion	B Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: C3 – Early Trials	blinatumomab Sensitive: C3 – Early Trials
CDKN2A deletion CDKN2A deletion	Mantle Cell Lymphoma Mantle Cell Lymphoma	CDKN2A deletion CDKN2A deletion	Mantle Cell Lymphoma Mantle Cell Lymphoma	ibrutinib Resistant: C3 – Early Trials	ibrutinib Resistant: C3 – Early Trials
CDKN2A deletion CDKN2A deletion	Acute Lymphocytic Leukemia ALL	CDKN2A deletion CDKN2A deletion	Acute Lymphocytic Leukemia ALL	blinatumomab Sensitive: C3 – Early Trials	blinatumomab Sensitive: C3 – Early Trials
CDKN2A deletion CDKN2A deletion	Melanoma Melanoma	CDKN2A deletion CDKN2A deletion	Melanoma Melanoma	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
CDKN2A deletion CDKN2A deletion	Gallbladder Cancer Gallbladder Cancer	CDKN2A deletion CDKN2A deletion	Gallbladder Cancer Gallbladder Cancer	palbociclib Resistant: C3 – Early Trials	palbociclib Resistant: C3 – Early Trials
CDKN2A deletion CDKN2A deletion	Glioma Glioma	CDKN2A deletion CDKN2A deletion	Glioma Glioma	vincristine + lomustine + procarbazine hydrochloride Resistant: C3 – Early Trials	vincristine + lomustine + procarbazine hydrochloride Resistant: C3 – Early Trials
CDKN2A deletion CDKN2A deletion	Hepatocellular Cancer HCC	CDKN2A deletion CDKN2A deletion	Hepatocellular Cancer HCC	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
CDKN2A deletion CDKN2A deletion	Melanoma Melanoma	CDKN2A deletion CDKN2A deletion	Melanoma Melanoma	palbociclib Sensitive: C3 – Early Trials	palbociclib Sensitive: C3 – Early Trials
CDKN2A deletion CDKN2A deletion	Pancreatic Cancer Pancreatic Cancer	CDKN2A deletion CDKN2A deletion	Pancreatic Cancer Pancreatic Cancer	palbociclib Resistant: C3 – Early Trials	palbociclib Resistant: C3 – Early Trials
CDKN2A deletion CDKN2A deletion	Gastric Adenocarcinoma Gastric Adenocarcinoma	CDKN2A deletion CDKN2A deletion	Gastric Adenocarcinoma Gastric Adenocarcinoma	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
CDKN2A deletion CDKN2A deletion	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	CDKN2A deletion CDKN2A deletion	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	T-lymphocyte cell therapy Resistant: C3 – Early Trials	T-lymphocyte cell therapy Resistant: C3 – Early Trials
CDKN2A deletion CDKN2A deletion	Prolymphocytic Leukemia Prolymphocytic Leukemia	CDKN2A deletion CDKN2A deletion	Prolymphocytic Leukemia Prolymphocytic Leukemia	alemtuzumab Resistant: C4 – Case Studies	alemtuzumab Resistant: C4 – Case Studies
CDKN2A deletion CDKN2A deletion	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	CDKN2A deletion CDKN2A deletion	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib + SNS-510 Sensitive: D – Preclinical	palbociclib + SNS-510 Sensitive: D – Preclinical
CDKN2A deletion CDKN2A deletion	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	CDKN2A deletion CDKN2A deletion	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ribociclib + SNS-510 Sensitive: D – Preclinical	ribociclib + SNS-510 Sensitive: D – Preclinical
CDKN2A deletion CDKN2A deletion	Ewing Sarcoma Ewing Sarcoma	CDKN2A deletion CDKN2A deletion	Ewing Sarcoma Ewing Sarcoma	ASP7487 Sensitive: D – Preclinical	ASP7487 Sensitive: D – Preclinical
CDKN2A deletion CDKN2A deletion	Ewing Sarcoma Ewing Sarcoma	CDKN2A deletion CDKN2A deletion	Ewing Sarcoma Ewing Sarcoma	palbociclib Sensitive: D – Preclinical	palbociclib Sensitive: D – Preclinical
CDKN2A deletion CDKN2A deletion	Renal Cell Carcinoma RCC	CDKN2A deletion CDKN2A deletion	Renal Cell Carcinoma RCC	temsirolimus Sensitive: D – Preclinical	temsirolimus Sensitive: D – Preclinical